The review discusses the results of using oral anticoagulants to improve the prognosis of patients after exacerbation of coronary artery disease. Based on a review of the available randomized clinical trials, the authors conclude that rivaroxaban at a dose of 2.5 mg twice daily has the best efficacy/safety ratio. Administration of rivaroxaban at the mentioned dose within 1 year after the development of acute coronary syndrome helps to reduce cardiovascular and total mortality and the risk of stent thrombosis.